The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage

New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022

Idorsia issues Notice of the 2022 Annual General Meeting of Shareholders

QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025

Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada

Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development

Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep

Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA

Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia

Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus

Johnson & Johnson partially converts its convertible loan

Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway

Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease

Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd

Idorsia announces the reference share price and the initial conversion price of convertible bonds successfully placed today

Idorsia successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company